BRD4 inhibition has been shown to inhibit transcriptional activation of the oncogene c-MYC (Delmore et al. 2011), which has been poised as particularly important for progression from low grade to high grade IDHmut glioma (Bai et al. 2016; Odia et al. 2013). The gene discussed is BRD4; the disease is central nervous system cancer.